Table 6.
A summary of GRPR targeted radiopharmaceuticals and their serum stabilities, tumour-to-blood (T:B) and tumour-to-muscle (T:M) ratios at a given time point post-injection
| [18F]AlF radioconjugate | Serum stability at 1 h (%)a | T:B ratio | T:M ratio | Time point p.i. (h)b | References |
|---|---|---|---|---|---|
| [18F]AlF-NODAGA-RM1 | > 90 | 10.29 | 14.58 | 2 | Liu et al. (2013) |
| [18F]AlF-NODAGA-AMBA | 72.5 | – | 8c | 2 | Liu et al. (2013) |
| [18F]AlF-NOTA-8-Aoc-BBN(7–14)NH2 | – | 49.51 | – | 1 | Dijkgraaf et al. (2012) |
| [18F]AlF-NOTA-4,7-lanthionine-BBN | > 80 (human serum) | 0.71 | 9.11 | 2 | Carlucci et al. (2015) |
| [18F]AlF-NOTA-2,6-lanthionine-BBN | > 80 (human serum) | 1.24 | 6.7 | 2 | Carlucci et al. (2015) |
| [18F]AlF-NOTA(6)-MATBBN | > 95 (human serum) | 9.44 | 30.70 | 1 | Pan et al. (2014) |
| [18F]AlF-JMV5132 | – | 106 | 305c | 1 | Chatalic et al. (2014) |
| [18F]AlF-NOTA-P2-RM26 | > 98 | 87 | 159 | 3 | Varasteh et al. (2013) |
aIntact parent radioconjugate in mouse serum after 1 h incubation, unless stated otherwise
bThe timepoint post-injection where T:B and T:M data is reported. T:B = tumour-to-blood ratio and T:M = tumour-to-muscle ratio calculated from ex vivo biodistribution data presented in the original manuscript and represented as a mean value
cEstimated from graphical data in the original manuscript